Mucosal immunology and oral vaccination

Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases: An Integrated View

Volumn , Issue , 2014, Pages 15-42

  García Hernández, Ana Lilia ^a   Rubio Infante, Néstor ^a   Moreno Fierros, Leticia ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Adaptive immune response; Adjuvant; Immunogenicity; Immunoprotection; Oral vaccination; Tolerance

Indexed keywords

EID: 84929935229     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-0850-9_2     Document Type: Chapter

References (74)

1. Aguilar JC, Rodríguez EG (2007) Vaccine adjuvants revisited. Vaccine 25:3752-3762
2. Alving CR (1991) Liposomes as carriers of antigens and adjuvants. J Immunol Methods 140(1):1-13
3. Artis D (2008) Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 8:411-420
4. Boyaka PN, Marinaro M, Jackson RJ, van Ginkel FW, Cormet-Boyaka E, Kirk KL, Kensil CR, McGhee JR (2001) Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J Immunol 166:2283-2290
5. Brandtzaeg P, Farstad IN, Haraldsen G (1999) Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today 20:267-277
6. Chabot S, Brewer A, Lowell G, Plante M, Cyr S, Burt DS, Ward BJ (2005) A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23:1374-1383
7. Chabot SM, Chernin TS, Shawi M, Wagner J, Farrant S, Burt DS, Cyr S, Neutra MR (2007) TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces. Vaccine 25:5348-5358
8. Chadwick S, Kriegel C, Amiji M (2010) Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 62:394-407
9. Chea EK, Fernández-Tejada A, Damani P, Adams MM, Gardner JR, Livingston PO, Ragupathi G, Gin DY (2012) Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes. J Am Chem Soc 134:13448-13457
10. Cheroutre H, Lambolez F, Mucida D (2011) The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol 11:445-456
11. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33:492-503
12. Coombes JL, Powrie F (2008) Dendritic cells in intestinal immune regulation. Nat Rev Immunol 8:435-446
13. Daniell H, Singh ND, Mason H, Streatfield SJ (2009) Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 14:669-679
14. Drulis-Kawa Z, Dorotkiewicz-Jach A (2010) Liposomes as delivery systems for antibiotics. Int J Pharm 387:187-198
15. Drummond DC, Zignani M, Leroux J (2000) Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39:409-460
16. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178-196
17. Eriksson K, Holmgren J (2002) Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14:666-672
18. Forrest ML, Koerber JT, Pack DW (2003) A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery. Bioconjug Chem 14:934-940
19. Freytag LC, Clements JD (2005) Mucosal adjuvants. Vaccine 23:1804-1813
20. Govea-Alonso DO, Rubio-Infante N, García-Hernández AL, Varona-Santos JT, Korban SS, Moreno-Fierros L, Rosales-Mendoza S (2013) Immunogenic properties of a lettuce-derived C4(V3) 6 multiepitopic HIV protein. Planta 238(4):785-92. doi: 10.1007/s00425-013-1932-y. Epub 2013 Jul. 30.
21. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ (2010) Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 10:453-460
22. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11:S45-S53
23. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A (2003) Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21:S89-S95
24. Holt PG, Strickland DH, Wikström ME, Jahnsen FL (2008) Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 8:142-152
25. Hong-Xiang S, Yong X, Yi-Ping Y (2009) ISCOMs and ISCOMATRIX. Vaccine 27:4388-4401
26. Iwasaki A (2010) Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol 10:699-711
27. Joffret ML, Morgeaux S, Laclerc C, Oth D, Zanetti C, Sureau P, Perrin P (1990) Enhancement of interleukin-2 activity by liposomes. Vaccine 8:385-389
28. Karmali PP, Chaudhuri A (2007) Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev 27:696-722
29. Kersten GF, Crommelin DJ (2003) Liposomes and ISCOMs. Vaccine 21:915-920
30. Kostrzak A, Cervantes Gonzalez M, Guetard D, Nagaraju DB, Wain-Hobson S, Tepfer D, Pniewski T, Sala M (2009) Oral administration of low doses of plant-based HBsAg induced antigen-specific IgAs and IgGs in mice, without increasing levels of regulatory T cells. Vaccine 27:4798-4807
31. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR (2002) Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 169:566-574
32. Kunkel EJ, Butcher EC (2002) Chemokines and the tissue-specific migration of lymphocytes. Immunity 16:1-4
33. Lassalle V, Ferreira ML (2007) PLA nano- and microparticles for drug delivery: an overview of the methods of preparation. Macromol Biosci 7:767-783
34. Lavelle EC, Grant G, Pusztai A, Pfüller U, O'Hagan DT (2000) Mucosal immunogenicity of plant lectins in mice. Immunology 99:30-37
35. Lawson LB, Norton EB, Clements JD (2012) Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Vaccine 30:142-154
36. Li X, Min M, Du N, Gu Y, Hode T, Naylor M, Chen D, Nordquist RE, Chen WR (2013). Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol 2013:387023
37. Ludwig C, Wagner R (2007) Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 18:537-545
38. Lycke N (2012) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12:592-605
39. Mallapragada SK, Narasimhan B (2008) Immunomodulatory biomaterials. Int J Pharm 364:265-271
40. Manicassamy S, Pulendran B (2009) Retinoic acid-dependent regulation of immune responses by dendritic cells and macrophages. Semin Immunol 21:22-27
41. Mantis NJ, Rol N, Corthésy B (2011) Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 4:603-611
42. Martin M, Metzger DJ, Michalek SM, Connell TD, Russell MW (2000) Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb. Infect Immun 68:281-287
43. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL (2000) CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19:950-957
44. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1:135-145
45. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5:905-916
46. Moreno-Fierros L, García-Hernández AL, Ilhuicatzi-Alvarado D, Rivera-Santiago L, Torres-Martínez M, Rubio-Infante N, Legorreta-Herrera M (2013) Cry1Ac protoxin from Bacillus thuringiensis promotes macrophage activation by upregulating CD80 and CD86 and by inducing IL-6, MCP-1 and TNF-α cytokines. Int Immunopharmacol 17(4):1051-66. doi: 10.1016/j. intimp. 2013.10.005. Epub 2013
47. Mowat AM (2003) Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 3:331-341
48. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148-158
49. Ogay ID, Lihoradova OA, Azimova ShS, Abdukarimov AA, Slack JM, Lynn DE (2006) Transfection of insect cell lines using polyethylenimine. Cytotechnology 51:89-98
50. Pabst O, Mowat AM (2012) Oral tolerance to food protein. Mucosal Immunol 5:232-239
51. Pavot V, Rochereau N, Genin C, Verrier B, Paul S (2012) New insights in mucosal vaccine development. Vaccine 30:142-154
52. Rappuoli R, Mandl CW, Black S, De Gregorio E (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11:865-872. doi:10.1038/nri3085
53. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23-32
54. Rescigno M (2011) The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol 32:256-264
55. Rojas-Hernández S, Rodríguez-Monroy MA, López-Revilla R, Reséndiz-Albor AA, Moreno-Fierros L (2004) Intranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis. Infect Immun 72:4368-4375
56. Rosales-Mendoza S, Salazar-González JA (2014) Immunological aspects of using plant cells as delivery vehicles for oral vaccines. Expert Rev Vaccines 13:737-749
57. Samatey FA, Imada K, Nagashima S, Vonderviszt F, Kumasaka T, Yamamoto M, Namba K (2001) Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling. Nature 410:331-337
58. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M (2007) Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28:1434-1442
59. Scott CL, Aumeunier AM, Mowat AM (2011) Intestinal CD103 + dendritic cells: master regulators of tolerance? Trends Immunol 32:412-419
60. Shale M, Schiering C, Powrie F (2013) CD4 (+) T-cell subsets in intestinal inflammation. Immunol Rev 252:164-182
61. Sharma S, Hinds LA (2012) Formulation and delivery of vaccines: ongoing challenges for animal management. J Pharm Bioallied Sci 4:258-266
62. Sharma S, Mukkur TK, Benson HA, Chen Y (2009) Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 98:812-843
63. Sinha VR, Trehan A (2003) Biodegradable microspheres for protein delivery. J Control Release 90:261-280
64. Strugnell RA, Wijburg OL (2010) The role of secretory antibodies in infection immunity. Nat Rev Microbiol 8:656-667
65. Takamura S, Niikura M, Li TC, Takeda N, Kusagawa S, Takebe Y, Miyamura T, Yasutomi Y (2004) DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther 11:628-635
66. Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M (2004) Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 82:617-627
67. Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2:727-735
68. Weimer ET, Ervin SE, Wozniak DJ, Mizel SB (2009) Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 27:6762-6769
69. Wong K, Sun G, Zhang X, Dai H, Liu Y, He C, Leong KW (2006) PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo. Bioconjug Chem 17:152-158
70. Woodrow KA, Bennett KM, Lo DD (2012) Mucosal vaccine design and delivery. Annu Rev Biomed Eng 14:17-46
71. Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Fujihashi K, Van Ginkel FW, Noda M, Takeda Y, McGhee JR (1997) A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A 94:5267-5272
72. Yih TC, Al-Fandi M (2006) Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 97:1184-1190
73. Yuki Y, Kiyono H (2009) Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines 8:1083-1097
74. Yusibov V, Streatfield SJ, Kushnir N (2011) Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 7:313-321